Genmab — November 2016
-
-
Spændebde nyhed: http://borsen.dk/nyheder/avisen/artikel/11/155025/artikel.html
-
Transcript fra Q&A: http://www.proinvestor.com/debat/75235
-
Karyopharm to Present Updated Phase 2b STORM and Phase 1b STOMP Clinical Data at the American Society of Hematology 2016 Annual Meeting https://www.firstwordpharma.com/node/1430098
-
Citat
fra artiklen om Karyopharm: "The results are particularly intriguing because the response rate to oral selinexor is comparable to that achieved with daratumumab or isatuximab" -
Godmorgen.
-
Tak resten. En fornøjelse at være tovholder med så mange mange positive og bidragende brugere vi har her på websitet samt i vores facebookgruppen.
-
Tak GB..Karyopharm har gode resultater med det orale produkt. Stormstudiet bliver derfor udvindet med yderligere 120
patienter -
med fem gange refraktær myelomatose.
-
Ja. Resultaterne er på linje med dem fra Darzalex. Mr. Ebbe spurgte Jan van de Winkel om konkurrenten i vores Q&A.
-
Jan svarede undvigende på spørgsmålet.
-
JohnW - du kan se Winkels svar på Ebbes spørgsmål om dette kl. 16:05 i Q/A i går
-
Stoffet er ikke rettet mod CD38, men mod proteinet XPO1.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind